Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adlette Inati

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Blood|July 18, 2022
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 studyMatthew M Heeney, Miguel R Abboud, Jessie Githanga, et al.
Blood Advances|January 18, 2024
von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand diseaseRobert F Sidonio, Ana Boban, Leonid Dubey, et al.
Pediatric Blood & Cancer|April 22, 2022
Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 yearsJeremie H Estepp, Ram Kalpatthi, Gerald Woods, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|February 8, 2012
Tracking human migrations by the analysis of the distribution of HLA alleles, lineages and haplotypes in closed and open populationsMarcelo A Fernandez Vina, Jill A Hollenbach, Kirsten E Lyke, et al.
Pediatric Blood & Cancer|August 20, 2019
Establishment of a formal program for retinoblastoma: Feasibility of clinical coordination across borders and impact on outcomeChristiane Al-Haddad, Ziad Bashour, Lina Farah, et al.
Pediatric Blood & Cancer|March 27, 2015
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 studyMariane De Montalembert, Miguel R Abboud, Anne Fiquet, et al.
The Lancet. Haematology|December 7, 2024
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Lucas Otieno, Bogdan Dumitriu, et al.
JAMA|April 20, 2021
Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical TrialJames F Casella, Bruce A Barton, Julie Kanter, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Blood|July 18, 2022
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 studyMatthew M Heeney, Miguel R Abboud, Jessie Githanga, et al.
Blood Advances|January 18, 2024
von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand diseaseRobert F Sidonio, Ana Boban, Leonid Dubey, et al.
Pediatric Blood & Cancer|April 22, 2022
Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 yearsJeremie H Estepp, Ram Kalpatthi, Gerald Woods, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|February 8, 2012
Tracking human migrations by the analysis of the distribution of HLA alleles, lineages and haplotypes in closed and open populationsMarcelo A Fernandez Vina, Jill A Hollenbach, Kirsten E Lyke, et al.
Pediatric Blood & Cancer|August 20, 2019
Establishment of a formal program for retinoblastoma: Feasibility of clinical coordination across borders and impact on outcomeChristiane Al-Haddad, Ziad Bashour, Lina Farah, et al.
Pediatric Blood & Cancer|March 27, 2015
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 studyMariane De Montalembert, Miguel R Abboud, Anne Fiquet, et al.
The Lancet. Haematology|December 7, 2024
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Lucas Otieno, Bogdan Dumitriu, et al.
JAMA|April 20, 2021
Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical TrialJames F Casella, Bruce A Barton, Julie Kanter, et al.
Pageof 7